Quarterly report pursuant to Section 13 or 15(d)

REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)

v3.23.2
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
6 Months Ended
Jun. 30, 2023
REVENUES FROM CONTRACTS WITH CUSTOMERS  
Schedule of disaggregation of net revenues

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three-Month Periods Ended June 30, 

​

Six-Month Periods Ended June 30, 

($ in thousands)

    

2023

    

2022

    

2023

    

2022

Qbrexza®

​

$

8,079

​

$

6,111

​

$

12,173

​

$

13,487

Accutane®

​

 

5,579

​

 

5,200

​

 

10,227

​

 

10,107

Amzeeq®

​

​

1,374

​

​

1,265

​

​

2,568

​

​

4,731

Zilxi®

​

​

572

​

​

555

​

​

886

​

​

1,297

Targadox®

​

​

664

​

​

2,756

​

​

1,457

​

​

5,390

Exelderm®

​

 

538

​

 

1,313

​

 

1,049

​

 

2,017

Ximino®

​

​

155

​

​

1,035

​

​

766

​

​

2,002

Total product revenues

​

$

16,961

​

$

18,235

​

$

29,126

​

$

39,031

Schedule of other revenue

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

Three-Month Periods Ended June 30,

    

Six-Month Periods Ended June 30,

($ in thousands)

    

2023

    

2022

    

2023

    

2022

Other revenue

 

$

211

 

$

56

​

$

259

 

$

2,556

Total other revenue

​

$

211

​

$

56

​

$

259

​

$

2,556